JP2017521482A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017521482A5 JP2017521482A5 JP2017514763A JP2017514763A JP2017521482A5 JP 2017521482 A5 JP2017521482 A5 JP 2017521482A5 JP 2017514763 A JP2017514763 A JP 2017514763A JP 2017514763 A JP2017514763 A JP 2017514763A JP 2017521482 A5 JP2017521482 A5 JP 2017521482A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- disease
- functional group
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 **C(CC(*)(C1)C2)(CC1(*)C1)CC21N Chemical compound **C(CC(*)(C1)C2)(CC1(*)C1)CC21N 0.000 description 18
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410235747.5A CN105294450B (zh) | 2014-05-29 | 2014-05-29 | 具有神经保护作用的金刚烷胺硝酸酯化合物及其制备和医药应用 |
| CN201410235747.5 | 2014-05-29 | ||
| PCT/CN2015/000314 WO2015180485A1 (zh) | 2014-05-29 | 2015-05-08 | 具有神经保护作用的金刚烷胺硝酸酯化合物及其制备和医药应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017521482A JP2017521482A (ja) | 2017-08-03 |
| JP2017521482A5 true JP2017521482A5 (enExample) | 2019-09-26 |
| JP6639483B2 JP6639483B2 (ja) | 2020-02-05 |
Family
ID=54698036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017514763A Active JP6639483B2 (ja) | 2014-05-29 | 2015-05-08 | 神経保護効用のあるアマンタジン硝酸エステル化合物及びその調製と医療応用 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP3150574B1 (enExample) |
| JP (1) | JP6639483B2 (enExample) |
| CN (3) | CN105294450B (enExample) |
| AU (1) | AU2015267968B2 (enExample) |
| CA (1) | CA2950452C (enExample) |
| ES (1) | ES2946987T3 (enExample) |
| IL (1) | IL249242B (enExample) |
| WO (1) | WO2015180485A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106397119A (zh) * | 2016-04-11 | 2017-02-15 | 上海博康精细化工有限公司 | 一种1，3-金刚烷二乙醇的制备方法 |
| KR101659055B1 (ko) * | 2016-05-10 | 2016-09-23 | 박소정 | 에피갈로카테킨 갈레이트 및 3,1-아다만탄디아세트산을 함유하는 알쯔하이머성 치매 치료 및 예방용 약학조성물 |
| CN106344551B (zh) * | 2016-08-22 | 2020-07-28 | 广州喜鹊医药有限公司 | 氨基金刚烷单硝酸酯类化合物在制备预防和治疗疾病药物中的应用 |
| CN107412211A (zh) * | 2017-08-04 | 2017-12-01 | 佛山喜鹊医药有限公司 | 氨基金刚烷胺单硝酸酯类化合物眼用组合物及其制剂和应用 |
| WO2019104020A1 (en) * | 2017-11-22 | 2019-05-31 | Panorama Research, Inc. | Aminoadamantyl nitrate compounds and their use to treat cns disorders |
| JP7296611B2 (ja) * | 2018-08-03 | 2023-06-23 | ビーエイチエヌ株式会社 | 一酸化窒素産生促進剤 |
| CN109206317B (zh) * | 2018-09-12 | 2021-07-09 | 青岛海蓝医药有限公司 | 一种金刚烷胺类硝酸酯衍生物的制备工艺 |
| CN109172560B (zh) * | 2018-10-15 | 2022-08-16 | 佛山喜鹊医药有限公司 | 氨基金刚烷硝酸酯类化合物或其药学上可接受的盐在预防和/或治疗肺部疾病中的应用 |
| US20230218548A1 (en) * | 2020-03-19 | 2023-07-13 | Eumentis Therapeutics, Inc. | Nitro-aminoadamantane compounds for the treatment of betacoronavirus infections |
| CN116725997A (zh) * | 2022-03-01 | 2023-09-12 | 广州喜鹊医药有限公司 | 氨基金刚烷单硝酸酯类化合物在制药领域中的应用 |
| CN117224520A (zh) * | 2023-11-01 | 2023-12-15 | 广州喜鹊医药有限公司 | (3-氨基-5-乙基金刚烷-1-基)硝酸甲酯及其药学上可接受的盐的医药用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6444702B1 (en) * | 2000-02-22 | 2002-09-03 | Neuromolecular, Inc. | Aminoadamantane derivatives as therapeutic agents |
| BR0116001A (pt) * | 2000-12-07 | 2004-07-06 | Neuromolecular Inc | Métodos para tratar distúrbios neuropsiquiátricos com antagonistas receptores nmda |
| CN1125033C (zh) * | 2001-08-29 | 2003-10-22 | 中国科学院广州化学研究所 | 美金刚胺盐酸盐的合成方法 |
| CA2426492C (en) * | 2002-05-31 | 2006-10-03 | H. Lundbeck A/S | A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease |
| CN1400205A (zh) * | 2002-08-30 | 2003-03-05 | 中国科学院广州化学研究所 | 美金刚胺盐酸盐的制备方法 |
| WO2005110468A2 (en) * | 2004-05-10 | 2005-11-24 | The Burnham Institute | Treatment of insulin resistance/metabolic syndrome to alleviate the risks of dementia |
| WO2007065036A2 (en) * | 2005-12-02 | 2007-06-07 | Neuromolecular Pharmaceuticals, Inc. | Therapeutic conjugates and methods of using same |
| WO2014015047A1 (en) * | 2012-07-17 | 2014-01-23 | The General Hospital Corporation | Compositions and methods to treat neurodegenerative diseases |
-
2014
- 2014-05-29 CN CN201410235747.5A patent/CN105294450B/zh active Active
- 2014-05-29 CN CN202410514635.7A patent/CN118290279A/zh active Pending
- 2014-05-29 CN CN202410514632.3A patent/CN118239847A/zh active Pending
-
2015
- 2015-05-08 WO PCT/CN2015/000314 patent/WO2015180485A1/zh not_active Ceased
- 2015-05-08 ES ES15798914T patent/ES2946987T3/es active Active
- 2015-05-08 JP JP2017514763A patent/JP6639483B2/ja active Active
- 2015-05-08 CA CA2950452A patent/CA2950452C/en active Active
- 2015-05-08 AU AU2015267968A patent/AU2015267968B2/en active Active
- 2015-05-08 EP EP15798914.6A patent/EP3150574B1/en active Active
-
2016
- 2016-11-27 IL IL249242A patent/IL249242B/en active IP Right Grant